Home › Funds › Redmile Group, LLC › IMNM
Redmile Group, LLC position in IMNM
IMMUNOME INC · Health Care
Redmile Group, LLC reported holding 4,911,590 shares of IMNM (IMMUNOME INC) in its Q2 2026 13F filing — a position valued at US$104.1M, representing 6.99% of its reported portfolio and ranking #4 among its reported holdings. Redmile Group, LLC has disclosed IMNM holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's IMNM position evolved
Redmile Group, LLC first disclosed a stake in IMNM in Q4 2023 at 3,879,415 shares (US$41.5M). The position peaked in Q4 2025 at 5,718,385 shares, worth US$122.8M. Across 11 filings, Redmile Group, LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 4,911,590 shares valued at US$104.1M — a reduction of -647,295 shares quarter over quarter.. Notable position changes include a 26% increase in Q1 2024 (shares fell 51% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 3.88M | $41.51M | New |
| Q1 2024 | 4.89M | $120.67M | Add |
| Q2 2024 | 4.89M | $59.16M | Hold |
| Q3 2024 | 4.89M | $71.49M | Hold |
| Q4 2024 | 4.83M | $51.27M | Reduce |
| Q1 2025 | 5.36M | $36.08M | Add |
| Q2 2025 | 4.87M | $45.31M | Reduce |
| Q3 2025 | 5.02M | $58.82M | Add |
| Q4 2025 | 5.72M | $122.83M | Add |
| Q1 2026 | 5.56M | $121.57M | Reduce |
| Q2 2026 | 4.91M | $104.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMNM and 13F data
IMNM (IMMUNOME INC) is a Health Care company. 48 other funds we track also report a position in IMNM — the largest reported positions include Enavate Sciences GP, LLC (US$76.6M), SILVERARC CAPITAL MANAGEMENT, LLC (US$42.7M), Sofinnova Investments, Inc. (US$36.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMNM
- Enavate Sciences GP, LLC 3.61M sh · $76.58M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.02M sh · $42.74M · Q2 2026
- Sofinnova Investments, Inc. 1.72M sh · $36.45M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M sh · $34.03M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 732.51K sh · $15.52M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 714.55K sh · $15.14M · Q2 2026
- Parkman Healthcare Partners LLC 594.20K sh · $12.59M · Q2 2026
- ALERUS FINANCIAL NA 383.42K sh · $8.12M · Q2 2026
- Atom Investors LP 297.49K sh · $6.30M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held IMNM?
Redmile Group, LLC has disclosed IMNM holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Redmile Group, LLC's current position in IMNM?
As of Q2 2026, Redmile Group, LLC holds 4.91M shares of IMNM (IMMUNOME INC), valued at $104.08M, representing 6.99% of its reported portfolio and ranking #4.
Has Redmile Group, LLC been buying or selling IMNM?
In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in IMNM. The position peaked in Q4 2025 at 5.72M shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Enavate Sciences GP, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, Sofinnova Investments, Inc., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.